-
公开(公告)号：EP4378959A2
公开(公告)日：2024-06-05
申请号：EP24167547.9
申请日：2012-05-02
发明人： DILUZIO, Willow , NGUYEN, Phuong M. , VARGA, Csanad M. , PALANIAPPAN, Vaithianathan , BROWN, Jason , FOX, Irving H. , SCHOLZ, Catherine , JENKINS, Erica Helen , ROSARIO, Maria
IPC分类号： C07K16/28
CPC分类号： A61K9/0019 , A61K47/12 , A61K47/14 , A61K47/183 , A61K47/26 , A61K39/39591 , A61K2039/50520130101 , A61K2039/5420130101 , A61K2039/54520130101 , C07K2317/2420130101 , C07K16/2839 , A61P1/00 , A61P1/04 , A61P1/16 , A61P1/18 , A61P29/00 , A61P31/18 , A61P37/06 , A61P43/00 , A61P3/10
摘要： Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
-
公开(公告)号：EP4376955A1
公开(公告)日：2024-06-05
申请号：EP22754498.8
申请日：2022-07-29
IPC分类号： A61P29/00 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/00 , C07C311/21 , C07D205/04 , C07D257/06 , C07D261/08 , C07D275/02 , C07D305/06 , C07D305/14 , C07D307/20 , A61K31/18
CPC分类号： C07C311/21 , C07D205/04 , C07D257/06 , C07D261/08 , C07D275/02 , C07D305/06 , C07D305/14 , C07D307/20 , A61P35/00 , A61P31/18 , A61P31/12 , A61P37/00 , A61P29/00 , C07C2601/0820170501 , C07C2601/0220170501 , C07C2601/1420170501 , C07C2601/0420170501 , C07C2602/5020170501 , C07C2602/1820170501 , C07C2603/6220170501 , C07C2603/9020170501
-
83.发明授权
-
公开(公告)号：EP1897548B2
公开(公告)日：2024-05-22
申请号：EP07021595.9
申请日：2004-03-01
IPC分类号： A01K67/027 , C12N15/63 , A61K31/70 , A61K39/00 , A61K39/38 , A61K39/395 , G01N33/53 , A01N43/04 , C07K16/00 , C12P21/08 , C07K14/705 , C07K16/28 , C12N5/0783 , C12N5/074 , C12N5/071 , A61K35/12 , A61P11/06 , A61P25/28 , A61P31/04 , A61P37/06
CPC分类号： A01K67/0271 , A01K67/0276 , A01K2267/038120130101 , A61K2035/12220130101 , A61K2039/50520130101 , A61K2039/5551620130101 , C07K14/70503 , C12N5/0636 , C12N2501/59920130101 , C12N2510/0020130101 , C12N2799/02720130101 , C07K16/2803 , A61P11/06 , A61P25/00 , A61P25/02 , A61P25/28 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/02 , A61P37/04 , A61P37/06 , A61P37/08 , A61P43/00 , A61K2039/8020180801 , Y02A50/30 , A61K39/4611 , A61K39/4644 , A61K39/4632 , A61K2239/3820230501 , A61K39/4621 , A61K39/464838
-
公开(公告)号：EP4309736A3
公开(公告)日：2024-05-08
申请号：EP23195199.7
申请日：2015-06-19
发明人： CARRA, Ernest A. , CHEN, Irene , KEATON, Katie Ann , ZIA, Vahid
IPC分类号： C07D498/18 , A61K31/537 , A61P31/18 , A61P43/00
CPC分类号： A61K31/513 , A61K31/553 , A61K31/675 , A61K31/683 , C07D498/18 , A61K45/06 , C07B2200/1320130101 , A61P31/18 , A61P43/00 , Y02A50/30
摘要： The present invention relates to crystalline forms and co-crystals of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-tritluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1b][1,3]oxazepine-10-carboxamide, the pharmaceutical formulations, and the therapeutic uses thereof. The present invention also relates to novel crystalline forms of sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-elate Form L
-
公开(公告)号：EP4359411A1
公开(公告)日：2024-05-01
申请号：EP22747171.1
申请日：2022-06-21
IPC分类号： C07D471/04 , C07D471/14 , C07D519/00 , A61P31/18 , A61P31/20 , A61P35/00 , A61P35/04 , A61K31/437 , A61K31/4375
CPC分类号： A61P31/18 , A61P31/20 , A61P35/00 , A61P35/04 , C07D471/14 , C07D471/04 , C07D519/00
-
公开(公告)号：EP3851459B1
公开(公告)日：2024-05-01
申请号：EP21152304.8
申请日：2011-09-21
IPC分类号： C07K19/00 , C07K14/54 , C07K14/075 , C12N15/62 , A61K38/17 , A61P35/00 , C12N1/00 , C12N5/00 , A61K38/00 , C07K14/715 , A61K38/20 , C07K16/18
CPC分类号： C07K2319/2120130101 , C07K2319/2220130101 , C07K2319/3020130101 , A61K38/00 , A61K38/1793 , A61K45/06 , C07K16/2887 , C07K2317/62220130101 , C07K2317/73220130101 , C12N15/62 , C12N15/09 , C07K14/5443 , C07K14/7155 , A61K38/2086 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/02 , A61P37/04 , A61P43/00
-
公开(公告)号：EP4316512A3
公开(公告)日：2024-04-24
申请号：EP23203010.6
申请日：2016-10-27
IPC分类号： C07K16/10 , C07K16/18 , C12N15/861 , A61P25/28 , A61K39/395 , A61K9/00 , A61K39/00
CPC分类号： A61K39/395 , A61K39/3955 , C07K16/1063 , C07K16/18 , A61K2039/5420130101 , C07K2317/62220130101 , C07K2317/7120130101 , C12N2750/1414320130101 , C12N15/86 , A61P21/02 , A61P25/00 , A61P25/06 , A61P25/14 , A61P25/16 , A61P25/28 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/18 , A61P31/20 , A61P31/22 , A61P39/02 , A61P9/00 , A61P9/10 , Y02A50/30
摘要： A composition comprising at least one AAV vector formulated for intrathecal delivery to the central nervous system is described. The composition comprises at least one expression cassette which contains sequences encoding an immunoglobulin construct linked to expression control sequences therefor and a pharmaceutically acceptable carrier. The immunoglobulin construct may be an immunoglobulin modified to have decreased or no measurable affinity for neonatal Fc receptor (FcRn).
-
公开(公告)号：EP3471765B1
公开(公告)日：2024-04-24
申请号：EP17731855.7
申请日：2017-06-15
IPC分类号： A61K39/12 , A61K31/047 , A61K31/198
CPC分类号： A61K2039/5550520130101 , C12N2740/1613420130101 , A61K33/06 , A61K9/0019 , A61K47/26 , A61K9/08 , A61K39/12 , A61K31/047 , A61K31/198 , A61P31/18 , A61P37/04 , A61K39/00
-
公开(公告)号：EP4351621A1
公开(公告)日：2024-04-17
申请号：EP22724606.3
申请日：2022-04-27
CPC分类号： A61K38/168 , A61P31/12 , A61P31/16 , A61P31/18 , C12N15/8279 , Y02A50/30
-
-
-
-
-
-
-
-
-
搜索结果
207 条记录 (耗时 0.022 秒)
